Stem cell transplant using half-matched donor for kids with blood cancer
Part of Blood & lymphatic, Cancer clinical trials.
This study tests a special stem cell transplant for children and young adults with certain high-risk blood cancers or bone marrow diseases. It uses a half-matched family donor and a technique to remove specific cells, which may lower the risk of side effects and help the body accept the new cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 30 years old or younger.
- You have a blood cancer or bone marrow disease that has not responded well to standard treatment or has come back.
- You need a family member who is at least half-matched to you for transplant.
- Your heart, liver, kidneys, and lungs must be working well enough.
- You must be free of active infections and not have a history of other cancers.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new way to prevent leukemia from returning after a half-matched stem cell transplant. It uses specially activated natural killer cells to attack remaining cancer cells. This may help people with high-risk or relapsed AML who have few other options.
This trial studies a type of stem cell transplant (bone marrow transplant) that uses a donor who is only half-matched to the patient, often a parent or sibling. It is for children and young adults with certain blood diseases, including sickle cell disease, thalassemia, bone marrow failure, and immune disorders. The transplant aims to replace the diseased blood-forming cells with healthy ones from the donor.
This trial tests a special stem cell transplant from a half-matched family donor, designed to reduce rejection and infection risk. It may include a targeted drug (blinatumomab) to help kill remaining cancer cells.
This trial tests a type of stem cell transplant that removes certain immune cells (alpha-beta T cells and CD19 B cells) from the donor cells. This may help prevent graft-versus-host disease and other complications in patients with blood cancers who do not have a matched sibling donor.
This expanded-access study offers a specific type of stem cell transplant preparation that removes certain immune cells (CD3 and CD19) from donor stem cells. It is for children who need a transplant but do not have a fully matched sibling donor and whose team cannot use the hospital’s usual matching device protocol.
This trial offers a stem cell transplant using a half-matched family donor and/or cord blood for people with high-risk or hard-to-treat cancers or blood disorders. It aims to provide a treatment option when a perfectly matched donor is not available.
Hear when a new Pediatric Hematologic Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.